Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
E. Vaniev (Moscow, Russian Federation), G. Kaminskiy (Moscow, Russian Federation), E. Veselova (Moscow, Russian Federation), N. Kuzmina (Surgut, Russian Federation), A. Samoilova (Moscow, Russian Federation), I. Vasilyeva (Moscow, Russian Federation). Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis. 3338

Member's Comments

No comment yet.

Related content which might interest you: The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008 Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018 Clinical-evolutive aspects of pulmonary tuberculosis at patients with chronic hepatitis Source: Annual Congress 2007 - Tuberculosis Year: 2007 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002 Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs Source: Eur Respir J 2007; 30: Suppl. 51, 657s Year: 2007 Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015 Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Transthyretin in patients with pulmonary tuberculosis co-infected HIV. Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010